New drug shows promise for stem cell transplant complication
NCT ID NCT05148299
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a drug called pegcetacoplan in 12 adults who developed a serious blood clotting condition (TA-TMA) after a stem cell transplant. The goal was to see how the drug moves through the body, if it helps, and if it is safe. Researchers measured drug levels and markers of inflammation over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pegcetacoplan
What this could lead to
If it works, this could point toward a treatment for a rare, serious complication of stem cell transplants.
What could go wrong
This is a very small, early pilot study with only 12 participants, so results may not apply to all patients. The drug may not improve outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Monza - S. Gerardo Hospital
Monza, 20900, Italy
-
Archet 1 hospital, Department of Clinical Hematology
Nice, 06200, France
-
Big Metropolitan Hospital Niguarda Regional Health Authority
Milan, 20162, Italy
-
CHU de Saint-Etienne
Saint-Priest-en-Jarez, 42270, France
-
City of Hope
Duarte, California, 91010, United States
-
General Hospital of Athens "Evangelismos"
Athens, 10676, Greece
-
General Hospital of Thessaloniki "G. Papanikolaou", Hematology Department - BMT Unit
Thessaloniki, 57010, Greece
-
Hospital San Giuseppe Moscati
Avellino, 83100, Italy
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Saint-Louis Hospital
Paris, Paris, 75010, France
-
United Hospitals Villa Sofia Cervello
Palermo, 90146, Italy
-
University General Hospital "Attikon"
Athens, Chaidari, 12462, Greece
-
University Hospital Puerta de Hierro Majadahonda
Madrid, 28222, Spain
-
University Polyclinic Foundation "Agostino Gemelli" - IRCCS
Roma, 00168, Italy